Royce & Associates’s Tandem Diabetes Care TNDM Stock Holding History

Royce & Associates’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$13.8M	Sell	848,233 -52,357	-6%	-$982K	0.13%	271
2026 Q2	$13.6M	Buy	900,590 +204,000	+29%	+$3.56M	0.11%	312
2026 Q1	$13.4M	Buy	696,590 +46,340	+7%	+$1.01M	0.13%	256
2025 Q4	$14.3M	Buy	650,250 +140,250	+28%	+$2.53M	0.14%	214
2025 Q3	$6.19M	Buy	+510,000	New	+$6.9M	0.06%	424
2021 Q3	–	Sell	-78,286	Closed	-$7.62M	–	1015
2021 Q2	$7.62M	Buy	78,286 +9,900	+14%	+$883K	0.05%	505
2021 Q1	$6.04M	Buy	68,386 +1,300	+2%	+$121K	0.04%	564
2020 Q4	$6.42M	Buy	67,086 +31,800	+90%	+$3.28M	0.05%	498
2020 Q3	$4M	Buy	35,286 +11,700	+50%	+$1.23M	0.04%	518
2020 Q2	$2.33M	Sell	23,586 -14,000	-37%	-$1.12M	0.03%	635
2020 Q1	$2.42M	Sell	37,586 -29,500	-44%	-$2.07M	0.03%	550
2019 Q4	$4M	Buy	67,086 +16,586	+33%	+$1.02M	0.04%	544
2019 Q3	$2.98M	Buy	+50,500	New	+$3.22M	0.03%	611

Other funds holding TNDM

Paradice Investment Management Denver, Colorado $594M AUM 28.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Fideuram Asset Management (Ireland) Dublin 1 $4.57B AUM 30.36% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Royce & Associates's TNDM Position: Q3 2026 in Review

Royce & Associates reduced its Tandem Diabetes Care (TNDM) stake by 5.8% in Q3 2026, selling an estimated $982K and leaving 848,233 shares worth $13.8M. The position accounts for 0.13% of the portfolio, ranked #271.

Royce & Associates first reported a position in TNDM in Q3 2019 and has held it in 13 quarters since. The position peaked at $14.3M in Q4 2025. 113 funds tracked by Wall St. Rank hold TNDM as of Q3 2026.

Royce & Associates held 848,233 shares of Tandem Diabetes Care worth $13.8M as of Q3 2026.
Royce & Associates sold 52,357 Tandem Diabetes Care shares in Q3 2026, an estimated $982K.
Tandem Diabetes Care made up 0.13% of Royce & Associates's portfolio in Q3 2026, its #271 holding.
Royce & Associates first reported a position in Tandem Diabetes Care in Q3 2019 and has held it in 13 quarters since.
Royce & Associates's Tandem Diabetes Care position peaked at $14.3M in Q4 2025.
113 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2026.

Based on Royce & Associates's 13F filing for Q3 2026, filed 9 Nov 2026.